• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
172218 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州

3 w5 q6 G  @4 _6 t, S可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
5 h+ u$ [  ~( D5 @7 V) _" }5 U9 y, G- o  S' l

0 G9 |* n; A6 h  \" _Sub-category:
( [4 m9 d5 x% z7 L. EMolecular Targets $ Z. c& }2 y# x! Z4 }: g- h% G
; m7 @3 V/ r0 a' [

! |- G2 F6 v, S/ E+ x/ xCategory:5 Y8 I8 G  J3 v1 J1 W3 t8 v/ z
Tumor Biology 7 q( c( d6 h3 u7 z6 [, b
6 \: n; [- ?2 w0 x* d0 r1 t
6 ]: ?) \, E- P5 g$ C& f! \
Meeting:
7 J4 B2 f$ k: j" A2 c2011 ASCO Annual Meeting
8 V' ~, H) N! B1 l$ O0 Q$ N" |$ w
2 f. G% \+ A& h& u" [" Y9 a4 T  u# A# S$ R6 E. o+ X' F0 ?
Session Type and Session Title:' q+ B5 @$ G% d; T+ Q
Poster Discussion Session, Tumor Biology # i% e  U. S3 V

/ h- ]9 e. I4 {
$ W9 w4 V5 |2 H- Y  NAbstract No:
* c" O0 S7 @9 e/ `, k( B10517 7 K: `6 l% s! w7 o: v
( W+ W  Y% O! ~" N
  ~+ m: {3 H6 Q+ W/ e5 k! p
Citation:  g. Z1 d1 j" q- T
J Clin Oncol 29: 2011 (suppl; abstr 10517)
2 D# T) ]0 j3 }* U$ k0 @
: ?9 x# j( o# b  V
1 K$ n* D! v8 Q" Q- AAuthor(s):
* o. U+ Q& \! o) d! h$ ]J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
6 d. E9 ?' y) y8 t& {: N5 `1 f. c4 G8 d9 i( w' J

# x8 c2 l5 c6 E2 h! A; }' p( I# @1 h$ F+ e' I, z6 O6 j9 U
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
0 a/ ?0 X& q% u) @3 b% m  I; Y9 L; I' x0 e
Abstract Disclosures% s7 v  L' t% [# }% C; ^1 C

" B# \: A' W' J# `( `" j6 {Abstract:
. A4 E. y* K5 @! [7 O' w4 _# L" k7 g9 a7 z
; M8 m) M" ?) c! j* @6 e
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
1 b! f8 A' n8 b
. f" {0 ~/ i; g/ | $ O# E1 G& b+ i, B1 [
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
8 _4 v0 n9 n3 T" k. @' _1 t没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

& m" P6 A9 x$ ]* A7 M$ [- j% T: N化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
% j' R0 G/ I1 Y4 l) K4 i' E, g& i易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。4 o' a" Z5 L9 ~
ALK一个指标医院要900多 ...
; `: z5 \0 z& l+ l; p' t
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
2 k; U3 g& i1 O, ?6 v, y. g, m# t2 ?+ p# i  s; i0 u  r
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表